Carolina Liquid Chemistries Promotes Family of Clinical Chemistry Analyzers
|
By LabMedica International staff writers Posted on 31 Jul 2018 |

Image: The EasyRA high-speed benchtop analyzer (Photo courtesy of Carolina Liquid Chemistries).
Carolina Liquid Chemistries (Greensboro, NC, USA) promoted its EasyRA high-speed benchtop analyzer, its family of clinical chemistry analyzers, CLC800, CLC1600, CLC6410, and extensive menu of reagents at the 70th annual AACC Scientific Meeting & Clinical Lab Expo held from July 31 – August 2. The company also introduced the Maglumi 2000 immunoassay analyzer at the event held in Chicago, USA.
Carolina Liquid Chemistries offers an extensive clinical chemistry reagent menu, ranging from general chemistries to urine drug screens and cardiovascular tests such as LpPLA2. The company markets a complete line of cost effective chemistry analyzers and service options for clinical laboratories of all sizes.
At AACC 2018, Carolina Liquid Chemistries highlighted the EasyRA, a high-speed benchtop clinical chemistry analyzer that accommodates the diverse needs of small to medium sized laboratories. Its all-in-one system allows laboratories to perform moderately complex urine drug screens and general chemistry tests on a single analyzer. With 300 tests per hour (480 with integrated ISE), an intuitive user interface, and the ability to analyze STAT samples in less than eight minutes, it is well suited for a variety of clinical laboratories located in satellite facilities, physician offices, pain management clinics, and urgent care centers.
In addition to the EasyRA, the company highlighted its family of floor model chemistry analyzers, the CLC800, CLC1600, and the CLC6410, which offer high throughputs from 400 to 900 to 3,200 photometric tests per hour. The FDA-cleared clinical chemistry analyzers are excellent for clinical laboratories located in mid-size group practices, large clinics, small and large hospitals or reference laboratories of all sizes.
Carolina Liquid Chemistries also highlighted its extensive reagent menu of products for both general chemistry and urine drug testing. This included 40 general chemistries, 27 urine drug screens, 15 immunochemistries and 24 special chemistries, including vLp-PLA2 (PLAC), Vitamin D (2-part), Procalcitonin (PCT) and Human Κ/λ Free Light Chain. Also on display at the event was the Maglumi 2000 immunoassay analyzer.
Carolina Liquid Chemistries offers an extensive clinical chemistry reagent menu, ranging from general chemistries to urine drug screens and cardiovascular tests such as LpPLA2. The company markets a complete line of cost effective chemistry analyzers and service options for clinical laboratories of all sizes.
At AACC 2018, Carolina Liquid Chemistries highlighted the EasyRA, a high-speed benchtop clinical chemistry analyzer that accommodates the diverse needs of small to medium sized laboratories. Its all-in-one system allows laboratories to perform moderately complex urine drug screens and general chemistry tests on a single analyzer. With 300 tests per hour (480 with integrated ISE), an intuitive user interface, and the ability to analyze STAT samples in less than eight minutes, it is well suited for a variety of clinical laboratories located in satellite facilities, physician offices, pain management clinics, and urgent care centers.
In addition to the EasyRA, the company highlighted its family of floor model chemistry analyzers, the CLC800, CLC1600, and the CLC6410, which offer high throughputs from 400 to 900 to 3,200 photometric tests per hour. The FDA-cleared clinical chemistry analyzers are excellent for clinical laboratories located in mid-size group practices, large clinics, small and large hospitals or reference laboratories of all sizes.
Carolina Liquid Chemistries also highlighted its extensive reagent menu of products for both general chemistry and urine drug testing. This included 40 general chemistries, 27 urine drug screens, 15 immunochemistries and 24 special chemistries, including vLp-PLA2 (PLAC), Vitamin D (2-part), Procalcitonin (PCT) and Human Κ/λ Free Light Chain. Also on display at the event was the Maglumi 2000 immunoassay analyzer.
Latest AACC 2018 News
- Mesa Biotech Showcases PCR Testing Platform at Clinical Expo
- Mindray Medical Unveils Chemiluminescence Immunoassay System at AACC 2018
- Abbott Diagnostics Displays Alinity Family of Systems
- Roche Diagnostics Highlights Latest Clinical Lab Solutions at AACC
- Sysmex Highlights Innovations in Flow Cytometry, Urinalysis and Hematology
- Ortho Clinical Diagnostics Unveils Next-Gen Analyzer at Lab Show
- Snibe Diagnostic Presents Immunoassay Systems and Biochemistry Analyzers
- Thermo Fisher Scientific Showcases Product Portfolio at Lab Trade Show
- EKF Diagnostics Highlights Assay Kit and POC Analyzer at AACC 2018
- Randox Laboratories Showcases Advances in Biotechnology at Clinical Lab Expo
- Beckman Coulter Life Sciences Highlights Clinical Flow Cytometry Portfolio
- Beckman Coulter Features New Hematology Analyzers and Lab Automation
- Orion Diagnostica Showcases Rapid Test and Molecular Platform at Lab Show
- Saladax Biomedical Launches Game-Changing Assays at AACC 2018
- SeraCare Life Sciences Promotes New AccuSpan Panel at Lab Expo
- Sekisui Diagnostics Showcases Clinical Chemistry and Immunoassay Analyzers
Channels
Clinical Chemistry
view channel
Maternal Blood Biomarkers Identify Risk of Preterm and Early-Term Birth
Preterm and early-term births can lead to lasting complications because vital organs continue to mature during the final weeks of pregnancy. Babies born too soon face increased risks of breathing difficulties,... Read more
Blood-Based Alzheimer’s Testing Platform Offers Rapid Results
Accurate identification of Alzheimer’s disease pathology often relies on cerebrospinal fluid analysis or positron emission tomography, which can be invasive, costly, and not widely accessible.... Read more
Simple Oral Swab Monitors Persistent Inflammation in Primary Ciliary Dyskinesia
Primary ciliary dyskinesia is a rare lung disease that affects about one in 7,500 to 10,000 live births worldwide. Symptoms can begin in the newborn period and progress to recurrent respiratory infections... Read more
Simple Blood-Based Cholesterol Efflux Assay Identifies High-Risk Coronary Plaque Features
Unstable coronary plaques are difficult to identify before they trigger acute cardiovascular events. Standard high-density lipoprotein (HDL) measurements do not always capture how well HDL particles function... Read moreMolecular Diagnostics
view channel
Point-of-Care PCR Panel Detects RSV, Influenza, and SARS-CoV-2 in Minutes
Respiratory syncytial virus, influenza, and SARS-CoV-2 remain major respiratory pathogens in ambulatory care. RSV is a particular priority because it can cause significant disease in infants, older adults,... Read more
Whole-Genome Sequencing Enables Genetic Diagnosis in Neurodevelopmental Disorders
Neurodevelopmental disorders include autism spectrum disorder and intellectual disability and can be difficult to diagnose because clinical presentations vary widely. In Italy, approximately 1% of children... Read more
Genetic Testing Identifies High-Risk Patients with Inflammatory Bowel Disease
Inflammatory bowel disease (IBD), encompassing ulcerative colitis and Crohn’s disease, is a lifelong, unpredictable condition that can require advanced therapies or surgery. More than half a million people in the U.... Read moreHematology
view channel
Next-Generation Hematology Platform Streamlines High-Complexity Lab Workflows
Sysmex America (Chicago, IL, USA) has introduced the next generation XR-Series, centered on the XR-10 Automated Hematology Module for high-complexity laboratories. The platform builds on the widely used... Read more
Blood Eosinophil Count May Predict Cancer Immunotherapy Response and Toxicity
Immune checkpoint inhibitors have improved outcomes across many cancers, yet only a subset of patients derive durable benefit and biomarkers to guide treatment remain limited. Eosinophils, best known for... Read moreImmunology
view channel
Lab-on-a-Chip Approach Advances Immune–Cancer Cell Interaction Analysis
Conventional cytotoxicity assays often average responses across thousands of cells, obscuring how individual immune cells engage and kill tumor cells. For immunotherapy evaluation, the precise sequence... Read more
Antibody Profiles Provide Clues to Long COVID Severity and Symptoms
Persistent symptoms after acute COVID-19 affect millions of people, causing fatigue, respiratory issues, and cognitive deficits that can be difficult to quantify with standard tests. Clinical teams lack... Read moreMicrobiology
view channel
Stronger Laboratory Services Support Timely Melioidosis Diagnosis Amid Global Spread
Melioidosis, a potentially fatal infection caused by Burkholderia pseudomallei, remains difficult to recognize because its symptoms can mimic tuberculosis and other illnesses. The disease is considered... Read more
Extracellular Vesicle Biomarker May Enable Noninvasive Monitoring of H. pylori
Helicobacter pylori infects an estimated 43.9% of the global population, affecting approximately 4.4 billion people worldwide. In many regions, including Africa, Eastern Europe, and Southeast Asia, prevalence... Read more
Rapid Molecular Screening Aims to Accelerate Hospital Infection Control for CPE
Drug-resistant infections remain a critical patient-safety threat in hospitals, with carbapenemase-producing Enterobacterales (CPE) among the most urgent concerns. In England, reports of acquired carbapenemase... Read morePathology
view channel
Stain-Free Imaging Platform Matches Standard Cancer Pathology
Histopathology underpins cancer diagnosis, but turnaround times and inter-laboratory variability can limit timely, consistent interpretation. Conventional staining relies on chemical dyes and multiple... Read more
New Companion Diagnostic Expands Precision Medicine in Prostate Cancer
Prostate cancer is a leading cancer diagnosis in men and becomes particularly aggressive when it presents as metastatic, hormone-sensitive disease. Tumors with loss of phosphatase and tensin homolog (PTEN)... Read more
Uncertainty-Aware AI Platform Supports Automated HER2 Assessment in Breast Cancer
Accurate assessment of human epidermal growth factor receptor 2 (HER2) is critical for breast cancer diagnosis and treatment selection, yet scoring variability and infrastructure requirements can complicate... Read moreTechnology
view channel
AI Platform Links Biomarker Results to Cancer Clinical Trials and Guidelines
Oncology teams must manage growing volumes of genomic data, rapidly evolving clinical trial options, and frequently updated care guidelines, all within tight clinic schedules. Translating complex tumor... Read more
Agentic AI Platform Supports Genomic Decision-Making in Oncology
Oncology care teams increasingly face the challenge of managing complex molecular diagnostics, evolving treatment options, and extensive electronic health record documentation. Translating multimodal data... Read moreIndustry
view channel
QIAGEN Enhances QIAcuity Platform with Gene Expression and Multiplexing Tools
QIAGEN (Venlo, Netherlands) has introduced additions to its QIAcuity dPCR ecosystem that focus on gene expression, expanded assay content, and workflow standardization for life sciences and biopharma users.... Read more









